Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. Moreover, traditional treatments such as che...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarantis, Panagiotis, Koustas, Evangelos, Papadimitropoulou, Adriana, Papavassiliou, Athanasios G, Karamouzis, Michalis V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031151/
https://www.ncbi.nlm.nih.gov/pubmed/32104548
http://dx.doi.org/10.4251/wjgo.v12.i2.173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031151/
https://www.ncbi.nlm.nih.gov/pubmed/32104548
http://dx.doi.org/10.4251/wjgo.v12.i2.173

Ejemplares similares